Roles of Advanced Glycosylation End Products (AGEs) in Diabetic Complication
碩士 === 台北醫學院 === 藥學研究所 === 87 === (1) Reducing sugars react with amino groups of proteins to form a variety of fluorescent advanced glycosylation end products (AGEs). Serum low molecular weight-AGEs (LMW-AGEs) have been linked to the development of diabetic-associated cardiac vasc...
Main Authors: | Yuang-Fong Lin, 林源峰 |
---|---|
Other Authors: | Horng-Mo Lee |
Format: | Others |
Language: | zh-TW |
Published: |
1999
|
Online Access: | http://ndltd.ncl.edu.tw/handle/66034677633361530901 |
Similar Items
-
The Role of Advanced Glycation End Products in Diabetic Vascular Complications
by: Sang Youl Rhee, et al.
Published: (2018-05-01) -
Application of Advanced Glycosylation End Products in Clinical Laboratory
by: Pan, Szu-Hua, et al.
Published: (1996) -
Advanced glycosylation endproducts in the pathogenesis of the late complications of diabetes and atherosclerosis
by: Lee, Wai Kwong
Published: (1996) -
Development of a Rapid Assay for Advanced Glycosylation End Products in Human Serum
by: Chwei-Yuh Lin, et al.
Published: (2001) -
Autoimmune response to advanced glycosylation end-products of human LDL
by: Gabriel Virella, et al.
Published: (2003-03-01)